3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pancreatic Neoplasms
1
Medulloblastoma
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Drug-drug Interaction,SHR3680
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Malignancies
1
Advanced Pancreatic Cancer
1
Interventions
Doxorubicin
26
pembrolizumab
24
Radiotherapy
20
Cyclophosphamide
18
Magnetic Resonance Spectroscopy
17
Specimen Handling
14
Nivolumab
14
Gemcitabine
13
Ifosfamide
12
Surgical Procedures, Operative
11
Biopsy
11
Radiation
10
X-Rays
8
Temozolomide
8
Ipilimumab
8
pazopanib
7
fludarabine
7
cabozantinib
7
Irinotecan
7
tazemetostat
6
liposomal doxorubicin
6
Trabectedin
6
Surveys and Questionnaires
6
Phantoms, Imaging
6
Blood Specimen Collection
6
olaparib
5
eribulin
5
atezolizumab
5
anlotinib
5
Vincristine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Digoxin
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled